U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07224529) titled 'Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction' on Oct. 31.
Brief Summary: This research study evaluates a prescription eye drop called Vevye(R) (cyclosporine 0.1%) for adults who have meibomian gland dysfunction (MGD), a common eye condition that can cause dry, irritated, or burning eyes.
If you join the study, after a short "run-in" period using artificial tears, you will receive Vevye twice a day for about 24 weeks (approximately six months). During that time you will attend several clinic visits where your eye symptoms, lid health, tear film, and meibomian gland function will be assessed. ...